Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075738 | 0.84 | MEN1 (0.37) | PKMTSHRHSD17B10ALDH1A1MEN1 | |
| SCHEMBL22887049 | 0.81 | PKM (0.38) | PKMSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30937226 | 0.77 | MEN1 (0.34) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL19766525 | 0.77 | MEN1 (0.34) | PKMTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL19639618 | 0.75 | GRM1 (0.37) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27190969 | 0.75 | MEN1 (0.33) | PKMMEN1KMT2A | |
| SCHEMBL22581351 | 0.75 | PKM (0.41) | PKMSMN1; SMN2RAB9ATSHRHSD17B10 | |
| SCHEMBL19639655 | 0.71 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL301039 | 0.70 | PKM (0.59) | PKMSMN1; SMN2RAB9ATSHRHSD17B10 | |
| SCHEMBL14031469 | 0.70 | FFAR3 (0.35) | SMN1; SMN2TSHRHSD17B10ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | WARATAH PHARMACEUTICALS INC. (CA) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028719-A1 | SCREENING METHODS FOR AMYLOID BETA MODULATORS | APP, BACE1, IAPP | PKM 3506/4885SMN1; SMN2 2222/4885RAB9A 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.